Houston, Texas, USA | July 21, 2026
Plus Therapeutics, through its wholly owned subsidiary CNSide Diagnostics, announced a regional coverage agreement with Medical Mutual for the CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) assay, effective July 1, 2026. The agreement extends reimbursement coverage to approximately 1.2 million health plan members across Ohio and Kentucky, increasing the assay’s total contracted coverage to approximately 127 million people in the United States. The expanded payer access represents a significant commercial milestone for the company’s precision diagnostic platform, which is designed to support the diagnosis, treatment monitoring, and clinical management of patients with leptomeningeal metastases, an aggressive form of metastatic central nervous system (CNS) cancer. By increasing reimbursement availability, Plus Therapeutics aims to improve access to advanced molecular diagnostics that enable earlier and more informed clinical decision-making for patients with difficult-to-diagnose CNS malignancies.
CNSide Assay Delivers High Clinical Accuracy for CNS Cancer Management
The CNSide® CSF Assay Platform is a proprietary laboratory-developed diagnostic test that quantitatively analyzes cerebrospinal fluid (CSF) to identify tumor cells that have spread to the central nervous system from primary carcinomas and melanomas. Clinical evidence supporting the platform includes 11 peer-reviewed publications, results from the FORESEE clinical trial, and extensive real-world clinical experience. Since its commercial launch in 2020, more than 11,000 CNSide tests have been performed across over 120 cancer institutions throughout the United States. The assay has demonstrated 92% sensitivity and 95% specificity, while influencing treatment decisions in 90% of evaluated cases, highlighting its value as a highly accurate diagnostic and disease-monitoring tool for patients with leptomeningeal metastases.
Expanded Insurance Coverage Strengthens Commercial Adoption
The agreement with Medical Mutual, one of Ohio’s largest health insurers, represents another important step in expanding payer reimbursement for CNSide Diagnostics’ precision oncology testing services. Broader insurance coverage is expected to improve physician access to the assay while reducing financial barriers for eligible patients requiring advanced CNS cancer diagnostics. The test is currently available exclusively through CNSide Diagnostics as a laboratory testing service for healthcare professionals across the United States. By expanding regional reimbursement agreements, the company continues to strengthen the commercial foundation for broader adoption of the CNSide platform, supporting its strategy to integrate precision diagnostics into routine oncology care for patients with metastatic CNS disease.
Advertisement
Integrated CNS Oncology Strategy Supports Future Growth
Beyond molecular diagnostics, Plus Therapeutics is advancing an integrated CNS oncology platform that combines precision therapeutics, molecular diagnostics, and data-driven technologies to improve outcomes for patients with brain and central nervous system cancers. The company’s lead therapeutic candidate, REYOBIQ™ (rhenium Re186 obisbemeda), is currently being developed for leptomeningeal metastases, recurrent glioblastoma, and pediatric brain cancers, complementing the diagnostic capabilities of the CNSide® platform. Plus Therapeutics also continues expanding its artificial intelligence and clinical data capabilities to support personalized treatment decisions and accelerate oncology drug development. As part of its broader corporate strategy, the company announced that it will officially change its corporate name to Cerenome, Inc. and begin trading on the Nasdaq under the ticker symbol CNSY effective August 3, 2026, marking a new phase in its evolution as an integrated precision oncology company focused on CNS cancer diagnosis and treatment.
Source: Plus Therapeutics press release
